Marcus Yountz
About
In The Last Decade
Marcus Yountz
20 papers receiving 303 citations
Hit Papers
Peers
Comparison fields: 5 of 32
- Neurology 245
- Pathology and Forensic Medicine 165
- Immunology 82
- Rheumatology 51
- Infectious Diseases 42
Countries citing papers authored by Marcus Yountz
This map shows the geographic impact of Marcus Yountz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus Yountz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus Yountz more than expected).
Fields of papers citing papers by Marcus Yountz
This network shows the impact of papers produced by Marcus Yountz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus Yountz. The network helps show where Marcus Yountz may publish in the future.
Co-authorship network of co-authors of Marcus Yountz
This figure shows the co-authorship network connecting the top 25 collaborators of Marcus Yountz. A scholar is included among the top collaborators of Marcus Yountz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcus Yountz. Marcus Yountz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | Ravulizumab in Aquaporin‐4–Positive Neuromyelitis Optica Spectrum Disorder breakdown → | 82 |
| 3 | 1 | |
| 4 | 1 | |
| 5 | 13 | |
| 6 | 31 | |
| 7 | 8 | |
| 8 | Efficacy and safety of eculizumab in patients with neuromyelitis optica spectrum disorder previously treated with rituximab: findings from PREVENT | 4 |
| 9 | 2 | |
| 10 | 3 | |
| 11 | 25 | |
| 12 | 0 | |
| 13 | 0 | |
| 14 | 28 | |
| 15 | 0 | |
| 16 | Impact of eculizumab on reported quality of life in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: findings from the PREVENT study | 2 |
| 17 | Impact of eculizumab on disability measures in patients with aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: phase 3 PREVENT study | 1 |
| 18 | Long-term Safety And Effectiveness Of Eculizumab In Neuromyelitis Optica Spectrum Disorder | 2 |
| 19 | 1 | |
| 20 | 0 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.